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Liraglutide improves liver 
microvascular dysfunction 
in cirrhosis: Evidence from 
translational studies
Fernanda Cristina de Mesquita1,3, Sergi Guixé-Muntet1,2, Anabel Fernández-Iglesias1, Raquel 
Maeso-Díaz1, Sergi Vila1, Diana Hide1, Martí Ortega-Ribera1, José Luís Rosa4, Juan Carlos 
García-Pagán1,2, Jaime Bosch1,2, Jarbas Rodrigues de Oliveira3 & Jordi Gracia-Sancho  1
Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, 
well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties. We 
evaluated the effects of liraglutide on HSC phenotype and hepatic microvascular function using diverse 
pre-clinical models of CLD. Human and rat HSC were in vitro treated with liraglutide, or vehicle, and 
their phenotype, viability and proliferation were evaluated. In addition, liraglutide or vehicle was 
administered to rats with CLD. Liver microvascular function, fibrosis, HSC phenotype and sinusoidal 
endothelial phenotype were determined. Additionally, the effects of liraglutide on HSC phenotype 
were analysed in human precision-cut liver slices. Liraglutide markedly improved HSC phenotype 
and diminished cell proliferation. Cirrhotic rats receiving liraglutide exhibited significantly improved 
liver microvascular function, as evidenced by lower portal pressure, improved intrahepatic vascular 
resistance, and marked ameliorations in fibrosis, HSC phenotype and endothelial function. The anti-
fibrotic effects of liraglutide were confirmed in human liver tissue and, although requiring further 
investigation, its underlying molecular mechanisms suggested a GLP1-R-independent and NF-κB-Sox9-
dependent one. This study demonstrates for the first time that liraglutide improves the liver sinusoidal 
milieu in pre-clinical models of cirrhosis, encouraging its clinical evaluation in the treatment of chronic 
liver disease.
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) are a new class of anti-diabetic medications that 
mimic the effects of incretin hormones1. As an incretin hormone, which is synthesized in response to food intake, 
GLP-1 can stimulate insulin release by pancreatic β-cells in a glucose-dependent manner and suppress glucagon 
secretion from α-cells2. The favourable actions of GLP-1 on glucose homeostasis are mediated through GLP-1 
receptors. However, native GLP-1 is rapidly degraded in circulation3. Liraglutide, a synthetic GLP-1RA that shares 
97% homology with the structure of human GLP-1, possesses a much longer circulating half-life, thereby making 
it a novel anti-diabetic drug suitable for once-daily injection1. Apart from the pancreatic islets, GLP-1 recep-
tors are present in many other tissues and, although its expression within the liver is not clear4, 5, recent studies 
demonstrated efficacy of GLP-1RA in liver diseases, such as NAFLD6, 7. In this regard, studies showed other bene-
ficial properties for this type of drugs, including anti-inflammatory and anti-oxidant8, 9, which are also important 
for the resolution of chronic liver disease (CLD).
Cirrhosis is the end stage of CLD that starts with deregulations in the phenotype of all hepatic cells leading to 
parenchymal and sinusoidal dysfunction10. In CLD, both architectural alterations of the liver parenchyma and 
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sinusoidal microvascular dysfunction contribute to the development of portal hypertension11. Architectural dis-
tortion of the cirrhotic liver is mainly due to excessive synthesis and deposition of extracellular matrix performed 
by deregulated fibrogenic cells mainly hepatic stellate cells (HSC)12. Indeed, in response to liver injury, HSC 
gradually transdifferentiate to an activated α-SMA-positive phenotype with extensive proliferation, and high 
vasoconstrictive and pro-inflammatory properties13, 14. It is widely accepted that activation of HSC is a key factor 
in the pathogenesis of liver fibrosis, CLD and portal hypertension15. Moreover, an intimate crosstalk between 
HSC and other sinusoidal cells further contributes to the development and aggravation of CLD16.
CLD may improve in response to injury cessation, blockade of pro-fibrogenic mediators or drug-induced HSC 
inactivation17. Unfortunately, current treatment options for CLD and its main complication portal hypertension 
are limited, and importantly there is no effective therapy available to efficiently ameliorate the hepatic microcir-
culation of CLD18. Therefore, novel therapeutic strategies based on EMA/FDA approved drugs with no systemic 
adverse effects are required to improve treatments for patients with CLD.
The primary purpose of the present study was to evaluate the effects of liraglutide on HSC phenotype, liver 
microvascular function and underlying mechanisms in pre-clinical models of CLD.
Results
Liraglutide improves the phenotype of Hepatic Stellate Cells. Effects of liraglutide on HSC pheno-
type were assessed in diverse pre-clinical models of CLD. After preliminary dose- and time-response experiments 
(Supplementary Fig. 1), we characterized liraglutide’s effects promoting the de-activation of cirrhotic primary 
hHSC and in the prevention of activation of control primary hHSC undergoing 7-day plastic activation. Both 
conditions showed a marked down-regulation in the activation markers collagen I and α-SMA at a concentration 
of 50 μM and after 72 h of treatment (Fig. 1A left and middle panels). The anti-fibrotic effects of liraglutide were 
further validated in human precision-cut liver slices (PCLS) (Fig. 1A right). In addition, the amelioration in 
hHSC phenotype in response to liraglutide was validated using a functional assay. As shown in Fig. 1B, liraglutide 
significantly prevented the contraction of primary hHSC.
The effects of liraglutide on activated HSC were further analyzed in LX-2, a widely-accepted human cell line 
mimicking activated HSC. These experiments indeed showed de-activation of LX-2 cells in response to liraglutide 
(Fig. 2A), which was associated with significant reductions in the pro-inflammatory and pro-fibrogenic markers 
TNF-α and TGF-βR1 (Fig. 2A).
Interestingly, LX-2 cells treated with liraglutide showed no significant changes in viability when compared 
to controls, as observed with the double staining with AO-PI (Fig. 2B). Contrarily, using two different analysis 
of cell proliferation, the trypan blue exclusion assay and the expression of the proliferative marker PDGFRβ, we 
herein show the anti-proliferative effects of liraglutide in HSC (Fig. 2C), which were accompanied with a marked 
reduction in their contraction ability (Fig. 2D). Altogether, validating the global improvement in HSC phenotype 
in response to liraglutide.
Similar beneficial effects of liraglutide were observed in rat primary HSC (Supplementary Fig. 2).
Liraglutide improves HSC phenotype and portal hypertension in CLD-rats. The potential benefi-
cial effects of liraglutide as a new therapeutic strategy to improve CLD and portal hypertension were also analyzed 
in vivo. After 15 days of treatment, CLD-rats treated with liraglutide displayed lower expression of α-SMA and 
PDGFRβ (Fig. 3A), accompanied by reductions in extracellular matrix synthesis and deposition as demonstrated 
by diminished collagen expression and hepatic fibrosis (Fig. 3B). No significant differences in TIMPs and MMPs 
were observed, thus suggesting that the peak of fibrinolysis already occurred (Supplementary Fig. 3). No effects 
on HSC viability (desmin expression) were observed, thus supporting the results obtained in vitro. Additional 
analysis of HSC phenotype in cells freshly isolated from CLD-rats treated with liraglutide, or vehicle, confirmed 
the marked beneficial effects of the drug promoting HSC deactivation (Fig. 3C).
Possible beneficial effects of liraglutide on hepatic and systemic hemodynamics in CLD-rats were also ana-
lyzed. Table 1 shows the morphometric and hemodynamic data from these animals. As expected, CLD-rats 
treated with liraglutide exhibited a slight but significant reduction in body weight, which is in agreement with 
previous studies19. Importantly, liraglutide-treated animals showed significantly lower portal pressure than 
vehicle-treated animals (11.6 ± 0.8 vs. 9.3 ± 1.0 mmHg; −20%; p = 0.03) without changes in portal blood flow, 
thus suggesting an improvement in the hepatic vascular resistance (9.5 ± 1.8 vs. 5.7 ± 1.3 mmHg·mL·min−1·g−1; 
−23%; p = 0.1). No effects of liraglutide on systemic hemodynamic or biochemical tests were observed.
Intrahepatic microcirculatory amelioration in response to liraglutide was further confirmed analyzing the 
hepatic microvascular phenotype. Indeed, LSEC from animals receiving liraglutide showed a significant reversal 
in their capillarization, as suggested by marked increments in fenestrae frequency and porosity (Fig. 4A), and a 
trend to higher nitric oxide bioavailability (Fig. 4B). In addition, characterization of the hepatic microvascular 
function ex vivo confirmed the global sinusoidal improvement, as demonstrated by reduction in HVR (Table 1) 
and improved liver vascular response to incremental doses of acetylcholine (Fig. 4C).
Liraglutide has a complementary effect with simvastatin improving HSC. Treatment of 
LX-2 cells with liraglutide did not modify the expression of the simvastatin-inducible transcription factor 
KLF2 (Supplementary Fig. 4 left). However, LX-2 treated with liraglutide or simvastatin showed reduced lev-
els of α-SMA in the same magnitude. Interestingly, when both drugs were combined further reduced α-SMA 
(Supplementary Fig. 4 right), altogether suggesting that liraglutide has a complementary effect to simvastatin 
improving the phenotype of activated HSC.
Liraglutide improves HSC phenotype and liver microcirculation probably through a GLP1-R 
independent mechanism. Analysis of GLP1-R expression in rat and human liver tissues and HSC showed 
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no detectable mRNA expression (Supplementary Fig. 5A), while a band corresponding to 53 kDa (predicted 
GLP-1R molecular weight) was only detected in LX-2 and barely present in cirrhotic and NASH human livers, 
but not in control human or rat livers (either control or cirrhotic) (Supplementary Fig. 5B). Accordingly, analysis 
of the GLP-1R secondary messenger PKA in rHSC and LX-2 treated with liraglutide did not show differences in 
its phosphorylation in comparison to cells treated with vehicle (Supplementary Fig. 5C), and incubation of LX-2 
with the GLP-1R antagonist Exendin 9–39 did not affect the de-activation effects of liraglutide (Supplementary 
Fig. 5D). Oppositely, liraglutide did repress the NF-κB molecular pathway (Supplementary Fig. 6).
Discussion
The major findings of the current study are that liraglutide promotes a marked amelioration in the phenotype of 
activated HSC, which in a pre-clinical model of chronic liver disease leads to significant improvement in portal 
hypertension and liver fibrosis. Importantly, the de-activating effects of liraglutide are herein demonstrated in 
human primary HSC and human liver tissue.
Liraglutide was developed as an anti-diabetic drug predictably acting on GLP-1R in pancreatic β-cells. 
Interestingly, different studies have demonstrated that these receptors may not be only limited to pancreatic β-cells. 
Considering the beneficial anti-inflammatory effects of GLP-1R agonists on cardiac fibrosis and NASH20–22, 
we aimed the present study at analyzing the effects of liraglutide in chronic liver disease (CLD).
Liver cirrhosis is the end stage situation of CLD being the main triggering factor a complex multicellular 
response of all hepatic cells. Indeed, in front of a chronic injury both parenchymal and non-parenchymal cells 
undergo profound changes in their phenotype, becoming highly de-regulated and ultimately leading to fibrosis 
and microvascular dysfunction16. The most relevant clinical consequence of sinusoidal cells de-regulation is the 
Figure 1. Amelioration of human primary HSC in response to liraglutide. (A) Expression of depicted proteins/
genes after in vitro treatment with 50 µM liraglutide or vehicle in: 1-HSC isolated from cirrhotic human livers 
(left), 2-quiescent human HSC undergoing in vitro activation (middle), and 3-human precision-cut liver slices 
(PCLS) (right). (B) Effects of liraglutide, or its vehicle, on the contraction of primary human HSC. n = 3 per 
experimental condition. *p < 0.05 vs. vehicle.
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development of portal hypertension, which derives both from pathological increases in intrahepatic vascular 
resistance and in portal blood flow. Considering the importance of HSC in CLD progression and aggravation, 
many studies focused on liver-specific drugs capable of inactivating the HSC, however few studies have advanced 
to the clinical stage23.
Our study is the first showing that liraglutide is able to improve the phenotype of HSC. Indeed, we performed 
dose- and time-dependent experiments indicating that liraglutide de-activates HSC as demonstrated by reduced 
expression of α-SMA and collagen. Similarly, we observed prevention of HSC activation in response to lira-
glutide, therefore suggesting possible beneficial effects of the drug when administered at early stages of CLD. 
Importantly, we planned this study as a bed to bench-side one, and not vice versa, therefore firstly evaluating the 
effects of liraglutide in human primary HSC, to latterly use different preclinical models of CLD to further study 
the molecular mechanisms of such ameliorations.
Hepatic stellate cells are activated in response to different liver injuries, or due to paracrine factors, promot-
ing tissue repair. Their response includes cell mobilization, proliferation, migration towards the lesion, and pro-
duction of extracellular matrix components. When continuous liver injury occurs, HSC become chronically 
activated, acquire high expression of pro-inflammatory, pro-fibrogenic and proliferative markers like TNF-α, 
TGFβ and PDGFRβ, ultimately representing the main cell-type responsible for fibrosis deposition24, 25. In the 
present study, we show that improvement in HSC phenotype in response to liraglutide was accompanied by 
marked reductions in the expression of these cytokines and proliferation markers, without affecting cell viability. 
Altogether suggesting that liraglutide promotes the de-activation of HSC, reduces their proliferation but does 
not induce cell apoptosis. Such anti-inflammatory effects, which are potentially optimal for the resolution of 
liver fibrosis in vivo, are quite different from previous studies showing concomitant de-activation and apoptosis/
necrosis of HSC in response to certain therapeutic strategies26–28. Importantly, analysis of HSC was not limited 
to molecular markers, but also included the cell contraction functional assay, which further confirmed the global 
improvement of HSC phenotype in response to liraglutide.
Additionally, we tested the possible beneficial effects of liraglutide when administered to human liver tissue. 
Taking advantage of the precision cut liver slices technique, considered an excellent tool to analyze the effects of 
drugs within the liver29, we observed marked reductions in the expression of α-SMA and collagen in response to 
liraglutide, therefore corroborating the anti-fibrotic effects of the drug.
Once the phenotype of HSC was characterized in vitro, we studied the effects of a physiological-relevant dose 
of liraglutide administered in vivo. Liraglutide treatment markedly improved both HSC and LSEC phenotypes. 
Figure 2. Underlying effects of HSC deactivation due to liraglutide. After 72 h of treatment with 50 µM 
liraglutide, LX-2 cells were assessed for markers of HSC activation (A), cell viability by double staining with 
acridine orange (green dense nuclei: apoptosis, indicated by arrowheads) and propidium iodide (red cells: 
necrosis) (B), HSC proliferation assessed by cell counting and expression of the proliferative marker PDGFRβ 
(C), and cell contraction (D). n = 3 per experimental condition. *p < 0.05 vs. vehicle.
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In fact, HSC activation markers collagen I, α-SMA and PDGFRβ were reduced in CLD rats receiving liraglu-
tide, which was accompanied by amelioration in LSEC fenestrae and NO bioavailability. Although we herein 
demonstrate direct action of liraglutide on HSC, we do not rule out possible paracrine interactions between 
both sinusoidal cell types in response to the drug16, 30. Importantly, global improvement in the sinusoidal phe-
notype led to regression of liver fibrosis, and to significant amelioration in the hepatic microvascular dysfunc-
tion. Indeed, liraglutide was able to reduce the PP in rats with CLD and portal hypertension. Such improvement 
in hepatic hemodynamics was mostly due to a significant improvement in the intrahepatic microvascular dys-
function, as demonstrated by the estimations of the in vivo and ex vivo HVR, and the analysis of the ex vivo 
Figure 3. Analysis of HSC phenotype and liver fibrosis in CLD-rats treated with liraglutide. (A) Expression 
of HSC activation markers (α-SMA and PDGFRβ) and Desmin in livers from TAA-CLD-rats treated for 15 
days with liraglutide or vehicle. (B) Analysis of hepatic fibrosis in rats described in A (collagen I expression and 
Sirius Red staining). (C) Analysis of the phenotype of HSC freshly isolated from rats described in (A). *p < 0.05 
vs. vehicle. n = 8 (A and B) and n = 3 (C) per group. Results are indicated as mean ± s.e.m.
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vasodilatory capacity in response to incremental doses of acetylcholine. Importantly, liraglutide did not affect 
systemic hemodynamics.
We next ascertained which could be the molecular pathway underlying liraglutide effects on HSC, and con-
sequently on liver microcirculation and fibrosis. First, and considering that liraglutide was formulated to act on 
GLP-1 receptor, we analyzed the expression of this receptor both in HSC isolated from rat and humans, and also 
in liver tissues. Surprisingly, GLP-1R mRNA was not detected in whole liver homogenates, primary human HSC 
Vehicle n = 11 Liraglutide n = 11 p value
PP (mmHg) 11.6 ± 0.8 9.3 ± 1.0 0.03
MAP (mmHg) 99.5 ± 7.2 89.9 ± 7.1 0.4
PBF (mL/min) 11.9 ± 1.0 11.5 ± 2.3 0.5
HVR (mmHg·min·mL−1·g−1) 9.5 ± 1.8 5.7 ± 1.3 0.1
ex vivo HVR 
(mmHg·min·mL−1·g−1) 1.6 ± 0.3 0.9 ± 0.04 0.07
Body weight pre-treatment (g) 289 ± 12 288 ± 7 0.5
Body weight post-treatment (g) 310 ± 9 274 ± 9 0.03
Liver weight (g) 8.4 ± 0.7 6.7 ± 0.4 0.1
AST (U/L) 105 ± 14 126 ± 14 0.3
ALT (U/L) 61 ± 10 67 ± 4 0.5
Albumin (g/L) 15.3 ± 1.3 16.3 ± 0.5 0.5
Cholesterol (mg/dL) 54.0 ± 8.3 44.6 ± 5.8 0.4
TG (mg/dL) 31.2 ± 5.6 26.8 ± 3.4 0.5
FFA (µmol/L) 506 ± 66 477 ± 55 0.7
Table 1. Effects of Liraglutide on hepatic and systemic hemodynamics, and biochemical parameters in 
rats with chronic liver disease due to chronic TAA administration, represented as mean ± s.e.m. PP, portal 
pressure; MAP, mean arterial pressure; PBF, portal blood flow; HVR, hepatic vascular resistance; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; TG, triglycerides; FFA, free fatty acids.
Figure 4. Effects of liraglutide on hepatic endothelial phenotype and microvascular function. (A) Liver 
sinusoidal fenestrae analysis by means of frequency (no. fenestrae/cell area) and porosity (fenestrae area/cell 
area) in TAA-CLD-rats treated with liraglutide or vehicle. (B) Hepatic nitric oxide (NO) bioavailability in rats 
described in A. (C) Hepatic microvascular function, calculated as the decrease in portal pressure in response 
to increasing doses of the endothelium-dependent vasodilator acetylcholine after vasoconstriction with 
methoxamine. *p < 0.05 vs. vehicle. n = 3 (A), n = 8 (B) and n = 5 (C) per group.
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or LX-2 cells using two different Taqman probes with PCR reactions going up to 60 cycles. At the protein level, 
western blot of hepatic samples using an antibody against GLP-1R showed signal in LX-2 lysates at the predicted 
GLP-1R molecular weight, but this signal was barely present in cirrhotic and NASH human tissue, while it was 
not detected in control human livers or rat liver tissue (either control or cirrhotic). These observations suggest 
that the beneficial effects of liraglutide in rat HSC and its effects in vivo would not be dependent on GLP-1R. 
Previous reports already showed contradictory results in terms of GLP-1R expression within the liver4, 5, and we 
are not totally convinced that the band detected by the antibody in human samples really corresponds to GLP-1R 
(as it is contradictory to the two specific mRNA TaqMan probes). In agreement, additional experiments showed 
lack of protein kinase A phosphorylation (marker of GLP-1R activation)31, 32 in response to liraglutide, and no 
differences in liraglutide-mediated HSC de-activation and proliferation when an antagonist of GLP-1R was used. 
Secondly, we analyzed the expression of the transcription factor Kruppel-like factor 2 (KLF2) in response to lira-
glutide since the effects of liraglutide on HSC were quite similar to those previously observed using statins26, 33–35. 
These experiments showed no up-regulation in response to the drug, moreover a synergistic effect of liraglutide 
and simvastatin de-activating HSC was observed, thus suggesting that they act by different pathways and could be 
used in combination at the bedside. Lastly, we evaluated the NF-κB molecular pathway, which plays a major role 
in liver fibrosis36 and is inhibited by liraglutide in the endothelium37. Interestingly, liraglutide down-regulated the 
expression of NF-κB, and also of its target gene Sox9.
With these results we cannot delineate the exact molecular mechanism driving liraglutide’s beneficial effects, 
which represents a limitation of the study. Nevertheless, considering the main role of NF-κB and Sox9 modulat-
ing HSC phenotype38, 39, and the findings described above, we herein suggest that in the specific scenario of CLD 
liraglutide may improve HSC phenotype and liver microcirculation through a GLP-1R independent mechanism, 
being the NF-κB–Sox9 pathway a solid candidate to mediate, at least in part, these effects. Desirable future exper-
iments, out of the scope of the present study, will clarify the specific receptor and the molecular mechanisms that 
mediate the beneficial effects of this drug in chronic liver disease.
In conclusion, the present study describes the anti-fibrotic effects of liraglutide both in rodent and, impor-
tantly, human pre-clinical models of chronic liver disease, therefore encouraging its application at the bedside as 
new therapeutic tool to improve cirrhosis and portal hypertension. Moreover, the potential results of the LEAN 
trial opens the possibility to use liraglutide not only to improve mild NASH7, but promote regression of advanced 
chronic liver disease. Desirable future trials will clarify this promising therapeutic alternative.
Materials and Methods
Animal models of chronic liver disease (CLD). The study was carried out in male Wistar rats (Charles 
River Laboratories, Barcelona, Spain). Animals were kept in environmentally controlled animal facilities. All 
procedures were approved by the Laboratory Animal Care and Use Committee of the University of Barcelona and 
were conducted in accordance with the European Community guidelines for the protection of animals used for 
experimental and other scientific purposes (EEC Directive 86/609). The personnel who prepared and adminis-
tered treatments and those that performed the experimental studies were different. Treatment’s codes were not 
open for interpretation of the results until the inclusion of all animals.
Induction of CLD by thioacetamide (TAA). TAA (Sigma Chemical Co) was dissolved in 0.9% normal saline 
approximately one hour before injection. Treatment groups received 200 mg/kg of TAA twice per week for a total 
of 12 weeks while control groups received the same volume of 0.9% normal saline18.
Induction of CLD by Carbon Tetrachloride (CCl4). Rats underwent inhalation exposure to CCl4 (Sigma) and 
received phenobarbital (0.3 g/L) in the drinking water. When rats developed ascites, toxicants administration was 
stopped40.
HSC isolation, culture and treatments. Isolation and culture of HSC. HSC were isolated from human 
(hHSC: control or cirrhotic) and rat (rHSC: control, TAA-CLD or CCl4-CLD) livers as described26 with minor 
modifications. Briefly, liver tissues were perfused with collagenase A, pronase and DNase (all Roche) in Gey’s 
Balanced Salt Solution (GBSS; Sigma), and dispersed cells were fractionated by density gradient centrifugation 
using 11.5% Optiprep (Sigma). HSC were cultured in Iscove’s Modified Dulbecco’s Media (IMDM, Invitrogen, 
Gibco) supplemented with fetal bovine serum, glutamine, antibiotics and amphotericin B. Results using primary 
HSC derived from at least 3 independent isolations and 3 replicates.
Immortalized human-activated HSC LX-2 were cultured as described11. Results using LX-2 derived from at 
least three replicates per experimental condition.
HSC treatments. HSC were incubated with liraglutide (Novo Nordisk), or its vehicle PBS, at different con-
centrations (1 μM, 10 μM, 50 μM and 100 μM) and for different periods of time (24 h, 48 h and 72 h). In vitro 
dosing of liraglutide was based on previous literature41. Considering that liraglutide exerted beneficial effects at 
50 μM and after 72 h of treatment, all subsequent experiments were performed using these experimental condi-
tions. Simvastatin was used in 10 µM dose alone and in combination with liraglutide. Exendin fragment 9–39 
(Sigma-Aldrich; 10 nM–1 uM) was used as a GLP-1R antagonist41.
Cell viability and proliferation. Equal number of LX-2 were seeded and after 72 h of liraglutide or vehicle, 
floating and adhered cells were collected and counted using a hemocytometer with trypan blue dye exclusion 
(FLUKA).
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Cell apoptosis. Cells were incubated with fresh medium containing 800 ng/mL Acridine Orange (AO) and 5 μg/
mL Propidium Iodide (PI) for 10 min at 37 °C and then washed with PBS. Fresh medium was added and cell 
death was examined using a fluorescence microscope (Olympus BX51, Tokyo, Japan) equipped with a digital 
camera (Olympus, DP72). AO is a metachromatic dye that stains both viable and apoptotic cells by intercalating 
into DNA and emits green fluorescence upon excitation at 480–490 nm. Nevertheless, nuclear condensation that 
occurs during apoptosis glares a more intense fluorescence. PI is excluded by viable cells but can penetrate cell 
membranes of dying or dead cells due to necrosis, emitting red fluorescence. Positive controls (in vitro ischemia 
and reperfusion), and negative controls (without dye) were included26.
Cell contraction. Contraction of HSC was performed as previously described with some modifications42. Briefly, 
culture plates were incubated with 1% BSA-PBS and afterwards filled with a mix of collagen (2 mg/mL) and human 
HSC (1–2 × 105 cells/mL). Once the gels were solidified, serum free IMDM with 50 µM liraglutide or vehicle was 
added. After 24 h, contraction was induced by adding 10% FBS for 24 h. Finally, the contraction area was digitalized 
and measured with ImageJ software. The results are expressed as % of contraction relative to the initial area of the gel.
Characterization of CLD-rats treated with liraglutide. Liraglutide administration. TAA-CLD-rats 
received by subcutaneous injections, twice a day, either liraglutide (0.5 mg/kg/day; n = 11) or vehicle (0.9% NaCl; 
n = 11) during 15 days. The dose was selected based on a conversion calculation starting from the dose used in 
humans and agreed with previous publications19, 43, 44. Administration of liraglutide to CLD-rats started one week 
after stopping the administration of TAA.
In vivo hemodynamics. Rats (n = 8 per group) were anesthetized with ketamine hydrochloride (100 mg/Kg; 
Merial Laboratories) plus midazolam (5 mg/kg; Laboratorios Reig Jofré) intraperitoneally. A tracheotomy was 
performed and a polyethylene tube PE-240 was inserted into the trachea to ensure a patent airway. PE-50 cathe-
ters were introduced into the femoral artery to measure mean arterial pressure (MAP; mmHg) and into ileocolic 
vein to measure portal pressure (PP; mmHg). A perivascular ultrasonic flow probe (Transonic System) was placed 
around the portal vein, as close as possible to the liver to avoid portal-collateral blood flow, in order to measure 
portal blood flow (PBF; mL∙min−1). Hepatic vascular resistance (mmHg·min·mL−1·g−1) was calculated as: PP/
PBF. Blood pressures and flows were registered on a multichannel computer based recorder (Power Lab; AD 
Instruments). Temperature of the animals was maintained at 37 ± 0.5 °C and hemodynamic data were collected 
after 20 min stabilization40, 45. Blood serum and plasma samples were stored for biochemical analysis.
Liver microvascular function. Immediately after recording in vivo hemodynamics, rat livers were isolated and 
perfused with Krebs buffer as previously described (n = 5 per group)45, 46. The perfused rat liver preparation 
was allowed to stabilize for 20 min before vasoactive substances were added. Intrahepatic microcirculation was 
pre-constricted by adding the α1-adrenergic agonist methoxamine (Mtx; 10−4 M; Sigma) to the reservoir, and 
liver microvascular function was assessed as concentration–response curves to cumulative doses of acetylcholine 
(Ach; 10–7–10−5 M; Sigma). Liver tissue was snap-frozen for subsequent molecular analysis.
Evaluation of hepatic fibrosis. CLD-rat livers were fixed in 10% formalin, embedded in paraffin, sectioned, and 
stained with 0.1% Sirius Red, photographed, and analyzed using a microscope equipped with a digital camera. The 
red-stained area was measured using Axiovision software26. Values are expressed as the mean of 8 fields per sample.
Sinusoidal characterization using Scanning Electron Microscope. In a sub-group of animals (n = 3 per group), 
after obtaining in vivo hemodynamics, livers were perfused through portal vein with a solution containing 2.5% 
glutaraldehyde and 2% paraformaldehyde and fixed overnight at 4 °C. Samples were washed 3 times with 0.1 M 
cacodylate buffer. Liver sections were fixed with 1% osmium in cacodylate buffer, dehydrated in ethanol, and 
dried with hexamethyldisilazane. Six randomly selected blocks from each animal were mounted onto stubs, 
and sputter coated with gold. 10 images per animal were acquired at a resolution of 15,000x using a Jeol 6380 
Scanning Electron Microscope (JEOL Ltd, Tokyo, Japan). Liver sinusoidal fenestrations were quantified using 
ImageJ Software (NIH)47.
Nitric Oxide bioavailability. Levels of cGMP, a marker of NO bioavailability, were analyzed in liver homogenates 
using an enzyme immunoassay (Cayman Chemical Co., Ann Arbor, MI) as previously described48.
RNA isolation and quantitave PCR. RNA from cells and tissue were extracted using RNeasy mini kit 
(Qiagen) and Trizol (Life Technologies), respectively. RNA quantification was performed using a NanoDrop spec-
trophotometer. cDNA was obtained using QuantiTect reverse transcription kit (Qiagen). Real-Time PCR were 
performed in an ABI PRISM 7900HT Fast Real-Time PCR System, using TaqMan predesigned probes for Col1A1 
(Hs00164004_m1, Rn01463848_m1), α-SMA (Hs00426835_g1, Rn01759928_g1), PDGFRβ (Hs01019589_m1, 
Rn01491838_m1), GLP1-R (Hs00157705_m1, Hs01006326_m1), Sox9 (Hs00165814_m1, Rn01751070_m1) 
and GAPDH or 18 S as endogenous controls. Results, expressed as 2−ΔΔCt, represent the x-fold increase of gene 
expression compared with the corresponding control group.
Western blot analysis. Cells were rinsed twice with PBS and lysed with Triton lysis buffer. Livers were 
homogenized in triton-lysis buffer for whole protein extraction. Aliquots from each sample containing equal 
amounts of protein were run on a sodium dodecylsulphate polyacrylamide gel, and transferred to a nitrocel-
lulose membrane. After the transfer, blots were blocked with Tris buffered saline containing 0.05% Tween-20 
and 5% non-fat dry milk or 3% albumin and subsequently incubated overnight at 4 °C with primary antibodies 
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against collagen I (ABT123, Millipore), α-SMA (A2547, Sigma), TNF-α (sc-1351, Santa Cruz Biotechnology), 
TGFβR (sc-398, Santa Cruz Biotechnology), GAPDH (sc-32233, Santa Cruz Biotechnology), p-PKA (4781, Cell 
Signaling), NF-κB (6956, Cell Signaling) and IκB (4812, Cell Signaling), all at 1:1000 dilution. Then membranes 
were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody at room tempera-
ture. Protein expression was determined by densitometric analysis using the LAS4000 (GE Healthcare) and Image 
Studio Lite software (LI-COR). Quantitative densitometric values of all proteins were normalized to GAPDH.
Precision-cut liver slices of human livers (PCLS). Fresh human liver biopsies were used to obtain 
250 μm slices using a Vibratome VT1000S (Leica Microsystems, Wetzlar, Germany). Samples were washed in PBS, 
soaked in 4% agarose solution (Ultrapure LMP Agarose, Invitrogen, Carlsbad, California, USA) for 20 min, and 
then orientated, mounted and immobilized using cyanoacrylate glue. Tissue slices were placed on organotypic 
tissue culture plate inserts (Millicell®-CM; Millipore). Tissues were maintained at 37 °C in a 5% CO2 humidified 
incubator using 1.1 mL of Williams’ Medium E supplemented with 1% inactivated fetal bovine serum, 2 mM 
L-Glutamine, 50 U/mL penicillin and 50 μg/mL streptomycin. Tissue slices were incubated with 50 µM liraglutide 
for 24 h. Sections were then transferred to a 1.5 mL tube and lysed for RNA isolation and qPCR29.
Ethics information. Quiescent hHSC (for prevention of in vitro activation) and PCLS were obtained from 
remnants from partial hepatectomy. Livers were considered control, but exhibited fibrosis staging between F1 
and F2. In all cases surgery was recommended to excise tumor metastasis from colon carcinoma. Cirrhotic hHSC 
(for in vitro de-activation) were isolated from remnant cirrhotic livers (all alcoholic aetiology) obtained after 
transplantation. The Ethics Committee of the Hospital Clinic de Barcelona approved the experimental protocol, 
samples manipulation and isolation procedures were carried out following good laboratory practices; in all cases 
patients signed the informed consent.
Statistical analysis. Statistical analysis was performed with the SPSS V.23.0 for Windows statistical package 
(IBM, Armonk, New York, USA). Results are expressed as mean ± s.e.m. Normality of samples was assessed using 
the Kolmogorov Smirnov test. For samples following a normal distribution, comparisons between groups were 
performed with the Student t test or analysis of variance, followed by a Bonferroni Post Hoc test when adequate. 
Otherwise, comparisons were assessed with the non-parametric Mann-Whitney U or Kruskal Wallis test when 
adequate. Differences were considered significant at a p value < 0.05.
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